Patents Examined by Robert Landsman
  • Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
    Patent number: 9139634
    Abstract: This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: September 22, 2015
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • PEG-interferon-beta formulations
    Patent number: 9138403
    Abstract: The invention relates to a liquid pharmaceutical composition comprising a pegylated IFN-? (PEG-IFN-?), an excipient, a surfactant and a buffer wherein said excipient is a polyol, wherein said surfactant is a non-ionic surfactant and wherein said buffer is a sodium acetate buffer.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: September 22, 2015
    Assignee: MERCK SERONO SA
    Inventors: Alessandra Del Rio, Joel Richard
  • Method for increasing M1 macrophages in a patient
    Patent number: 9139652
    Abstract: The invention is generally directed to promoting M1-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-IR in a patient by assessing the in vivo or in vitro activation of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-IR on a subject being treated.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: September 22, 2015
    Assignee: Transgene SA
    Inventors: Hélène Haegel, Rêmy Hallet
  • Myomegalin variant 8
    Patent number: 9133258
    Abstract: The present invention provides a novel myomegalin isoform—myomegalin variant 8 (MMG8). The myomegalin variant 8 regulates microtubule organization at the Golgi apparatus, protein modification, secretion and trafficking, and cell proliferation. The present invention also provides nucleic acid molecules encoding the myomegalin isoforms, and vectors and host cells containing the nucleic acid molecules. Also provided are fusion constructs comprising the myomegalin isoform and antibodies that bind specifically to the myomegalin isoforms of the present invention. The present invention further provides uses of the myomegalin isoform as a diagnostic biomarker and as a target for screening for therapeutics for diseases such as cancer, diabetes, and lysosomal storage diseases.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: September 15, 2015
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Zhe Wang, Robert Zhong Qi
  • Nucleic acids encoding human glucagon receptor antibodies
    Patent number: 9127068
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 8, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Methods of using lung or bronchial epithelial cells to identify bitter taste modulators
    Patent number: 9128079
    Abstract: Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: September 8, 2015
    Assignees: The Coca-Cola Company, The University of North Carolina
    Inventors: Harish Radhakrishna, Michael D. Brown, David Peter Siderovski, Adam Kimple, Staci Padove Cohen
  • Polymer conjugates of interferon-beta with enhanced biological potency
    Patent number: 9125880
    Abstract: Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non-glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: September 8, 2015
    Assignee: Mountain View Pharmaceuticals, Inc.
    Inventors: Mark G. P. Saifer, Alexa L. Martinez, L. David Williams, Merry R. Sherman
  • Administration of relaxin to treat nephrogenic diseases of water imbalance involving aquaporin-4
    Patent number: 9119833
    Abstract: The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 1, 2015
    Assignees: University of Melbourne, University of Florida Research Foundation, Inc.
    Inventors: Laura Parry, Kirk Conrad
  • Light-inducible system for regulating protein stability
    Patent number: 9115184
    Abstract: Disclosed herein are a light-inducible system and method for rapidly and reversibly modulating protein stability and function. This system and method employs conditionally stable protein domains that regulate the degradation of a fusion protein depending upon the presence or absence of a particular light source.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: August 25, 2015
    Assignee: The Board of Trustees of The Leland Stanford Junior University
    Inventors: Kimberly M. Bonger, Rishi Rakhit, Thomas J. Wandless
  • cDNA-derived nucleic acids encoding red-shifted channelrhodopsins
    Patent number: 9102747
    Abstract: Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: August 11, 2015
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John Lee Spudich, Elena G. Govorunova, Oleg A. Sineshchekov
  • Anti-S1P antibody treatment of patients with ocular disease
    Patent number: 9102718
    Abstract: The present invention relates to methods that involve administration of an anti-S1 P antibody or antibody fragment or derivative to a subject having or suspected of having an ocular disease or condition, including one involving choroidal neovascularization, in order to achieve a desired effect. Such effects include reducing the size of a choroidal neovascularization lesion in the eye, decreasing or resolving retinal pigment epithelial detachment, decreasing central retinal lesion thickness, and preserving or improving visual acuity. Pharmaceutical compositions comprising an anti-S1 P antibody for ocular administration are also provided. The compositions and methods are particularly useful for treating subjects having age-related macular degeneration, particularly exudative or wet age-related macular degeneration.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: August 11, 2015
    Assignee: Lpath, Inc.
    Inventors: Glenn L. Stoller, Marina Safonov, Scott R. Pancoast, James Leigh Hsu
  • Antibodies which bind to signal peptide-containing molecules
    Patent number: 9102745
    Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: August 11, 2015
    Assignee: INCYTE CORPORATION
    Inventors: Preeti G. Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice K. Au-Young, Henry Yue, Chandra S. Arvizu, Roopa M. Reddy, Jennifer L. Jackson, Olga Bandman
  • Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia
    Patent number: 9095609
    Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 4, 2015
    Assignees: UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (C.S.I.C.)
    Inventors: Carlos Belmonte Martnez, Juana Gallar Martinez, Antonio Ferrer Montiel, Asia Fernández Carvajal, Félix Viana De La Iglesia
  • Production of IFN-lambda by conventional dendritic cells
    Patent number: 9090897
    Abstract: In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-?) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-? and/or generating or obtaining a population of IFN-? producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: July 28, 2015
    Assignee: Bavarian Nordic A/S
    Inventor: Hubertus Hochrein
  • Fed-batch method of making anti-TNF-alpha antibody
    Patent number: 9090867
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: July 28, 2015
    Assignee: AbbVie Inc.
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang D. Chang, Thomas Seewoester
  • Anti-TNF antibody formulations
    Patent number: 9085619
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 21, 2015
    Assignee: AbbVie Biotechnology LTD.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe
  • Compositions comprising inhibitors of EPH receptor expression in tumor stem cells and methods of treatment thereof
    Patent number: 9078857
    Abstract: The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: July 14, 2015
    Assignee: StemGen S.P.A.
    Inventors: Angelo Luigi Vescovi, Elena Binda
  • Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease
    Patent number: 9079955
    Abstract: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 14, 2015
    Assignee: Avaxia Biologics, Incorporated
    Inventor: Barbara S. Fox
  • Method for treating psoriasis
    Patent number: 9078876
    Abstract: Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one or more minor antigens. The injected cells are stimulated with a pro-inflammatory cytokine, e.g. IL-12, and a polyclonal activating agent. The injected animals develop a chronic skin disorder that includes histological features observed in human psoriasis, e.g. rete pegs, severe acanthosis and infiltration of Th1 cells into the dermis.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 14, 2015
    Assignee: Abbvie Biotherapeutics, Inc.
    Inventors: Rolf O. Ehrhardt, Kenneth Hong
  • Methods for identifying modulators of tumor necrosis factor receptors
    Patent number: 9081017
    Abstract: This invention relates to the identification and characterization of specific cellular responses which are associated with tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 1 (TNFR2). Selective modulation of these tumor necrosis factor receptors (TNFRs) Selective modulations of these responses may be useful in the promotion or inhibition of cell growth, for example, in the treatment of disease conditions, including cardiovascular and kidney diseases. Therapeutic methods employed selective TNFR1 and TNFR2 modulators are provided, along with screening methods for the identification of selective TNFR1 and TNFR2 modulators useful in such methods.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: July 14, 2015
    Assignees: Cambridge Enterprise Limited, Yale University
    Inventors: John Bradley, Jordan Pober, Paul Clark, Wang Min, Martin Kluger